跳至主要内容
临床试验/NL-OMON38470
NL-OMON38470
已完成
不适用

In vivo REsponse evaluation of colorectal liver metastases during systemic therapy using optical SPECTroscopy techniques: a pilot study - RESPECT study

Philips Research0 个研究点目标入组 22 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
colorectal livermetastases
发起方
Philips Research
入组人数
22
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational invasive

研究者

入排标准

入选标准

  • \- Non\-resectable colorectal liver metastases
  • \- Liver metastases of which a histological biopsy can safely be obtained:
  • \* Patients with safely accessible liver lesions according to an intervention\-radiologist.
  • \* Patients not known with bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgery.
  • \* Patients not using any anti\-coagulant medication at the time of biopsy: all aspirin derivatives, NSAID\*s, coumarines, platelet function inhibitors, heparins (including LMWHs) and oral factor Xa inhibitors are not allowed, unless medication can either be safely stopped or counteracted.
  • \* Adequate hematology and coagulation status as measured by:
  • \* Hb \> 6\.0 mmol/L
  • \* Platelet count \> 100 x 109/L
  • \* PT \< 1\.5 x Upper limit of normal (ULN)
  • \* APTT \< 1\.5 x ULN

排除标准

  • \- Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy
  • \-Patients who have higher risk of bleeding, such as patients with coagulopathy or patients who receive anticoagulants

结局指标

主要结局

未指定

相似试验